Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAX-ESR1 study in ESR1-mutated metastatic breast cancer
NL-OMON46354Completed
- Sponsor
- Erasmus MC
- Start
- Dec 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of paclitaxel and docetaxel in breast cancer, sponsored by Erasmus MC. Primary endpoint: Progression-free survival rate at 6 months. Started Dec 2017; status: completed.
02
Drugs
paclitaxeldocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON46354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46354.